Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

tfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalininclude risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective as consolidation therapy following treatment with a regimen of fludarabine and mitoxantrone for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com


SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Heart Valve Repair ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart Valve Repair ... human heart which control the flow of blood ... heart valve diseases such as valvular stenosis, valvular ...
(Date:8/27/2014)... 27, 2014  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the Morgan Stanley Global Healthcare Conference on ... You are invited to listen to the live discussion ... access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP .  A recorded ... after conclusion of the live event and accessible at ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
(Date:8/27/2014)... 27, 2014 With most forms ... sense to use hearing protection when exposed to ... are many different forms of hearing protection ... provide hearing protection training and devices for workers ... industries. The National Institute of Occupational Safety and ...
(Date:8/27/2014)... time you experienced worrisome medical symptoms, did you ... professional? If so, you,re not alone. Consumers are ... support groups to gather anecdotal information and advice, ... trustworthy sources. New research to be presented at ... the characteristics of consumers who use the Internet ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
(Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... occurs when red blood cells are in short supply or ... body does not get enough oxygen, since there are fewer ...
(Date:8/27/2014)... 8/27/14)Dartmouth cancer researchers developed and tested an advanced ... interactions that contribute to disease as published yesterday ... The approach fills a gap in current analyses. ... interactions among genetic and environmental factors. When many ... versus those that reflect chance combinations among affected ...
Breaking Medicine News(10 mins):Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 2Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 3Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... may lower the risk of a type of kidney malignancy ... ,The researchers at Brigham and Women's Hospital in Boston found ... alcoholic beverage a day were about 30 percent less likely ... they found in people who drank beer, wine or liquor. ...
... US President set a target of ten years for developing ... ,"We have learned in that period of time ... senior vice president for research and development at the International ... vaccine research increased from $186 million in 1997 to $759 ...
... rates among Japanese have generally tended to be high. Now ... hit a record 65 in 2006, compared to 42 ... ,The number of workers who received compensation for work-induced ... percent from a year earlier, he said. The number of ...
... of Health and Child Welfare, Dr. David Parirenyatwa, says ... West have severely compromised the country's health delivery ... ongoing World Health Assembly in Geneva, Switzerland, to join ... these sanctions. He calls the sanctions an unacceptable ...
... have agreed on a $5-billion initiative with major banks to ... the first such enterprise to combat climate change. ... this week with a summit in New York attended by ... to discuss climate change. ,Clinton's initiative launched on ...
... developed a model that could improve the treatment ... combine current clot-busting medication with below-normal body temperatures ... lowering a patients temperature reduces the metabolic activity ... cell damage and death. ,The FDA-approved ...
Cached Medicine News:Health News:AIDS Vaccine Still a Long Way Off 2Health News:Workplace Stress Leads to Rising Suicide Rate in Japan 2Health News:Sanctions Imposed On Zimbabwe Can Threaten International Health Security 2Health News:World Cities Join Hands to Combat Climate Change 2Health News:Researchers Develop Model That Aids in Treating Stroke Patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: